^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunoproteasome inhibitor

    Related drugs:
    Apply
    A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma (NCT03875079)
    Phase 1
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/29/2023
    Initiation :
    06/24/2019
    Primary completion :
    07/14/2022
    Completion :
    07/14/2022
    PD-L1 • BRAF • CD8 • FOXP3
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • simlukafusp alfa (RG7461)
    Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) (NCT03063762)
    Phase 1b
    Hoffmann-La Roche
    Completed
    Last update posted :
    02/17/2023
    Initiation :
    03/20/2017
    Primary completion :
    06/14/2021
    Completion :
    06/14/2021
    PD-L1
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)
    A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C) (NCT02627274)
    Phase 1a/1b
    Hoffmann-La Roche
    Completed
    Last update posted :
    11/22/2022
    Initiation :
    12/07/2015
    Primary completion :
    11/10/2022
    Completion :
    11/10/2022
    CD20
    |
    EGFR positive
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • simlukafusp alfa (RG7461)